ER-REBOA PLUS Catheter REBOA (occlusion catheter) Distal Intended for temporary occlusion of large vessels and blood pressure monitoring including patients requiring emergency control of hemorrhage ...

The first evaluation for subclavian artery occlusive disease should always be a simple measurement of bilateral brachial artery blood pressures. A significant difference between the two ...

Angiography revealed occlusive thrombus in the left CIA extending to the left CFA and in the ... The initial experience of the Artix Thrombectomy System highlights its promising potential to advance ...

The hospital's state-of-the-art American Heart and Vascular Institute performed a challenging surgery including open ...

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic ...

Background Occlusion of the internal carotid artery (ICA) may extend into the middle or anterior cerebral artery (ICA-T) or be confined to the intracranial (ICA-I) or extracranial segment (ICA-E).

AI-enabled ECG biological age (ECG-BA) improves disease risk classification beyond chronological age, enhancing early ...

Peripheral arterial disease (PAD) is a common but under-recognized problem affecting older patients. Intermittent claudication is the most frequent symptom of PAD, although the diagnosis of PAD is ...

The interventional approach to treat peripheral artery occlusive disease (PAOD) as a treatment of choice is gaining continuous acceptance. SeQuent ® Please OTW offers a targeted, polymer-free and ...

Endovascular treatment (EVT) of stroke with large-vessel occlusion is known to be safe and effective. The effect of EVT for occlusion of medium or distal vessels is unclear. We randomly assigned ...

Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to ... occlusions in a middle-cerebral-artery branch. A modified Rankin scale ...

Aplagon announces EUR 7 million financing to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2A trials: Helsinki Tuesday, February 4, 2025, 16:00 Hrs [IS ...